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Embolic	  stroke	  of	  unknown	  source	  (ESUS)	  in	  patients	  with	  atrial	  septum	  defect	  
and	  patent	  foramen	  ovale:	  difference	  and	  similarities	  
 C.	  Delabays1,	  P.	  Correia1,	  E.	  Eeckhout2,	  A.	  Delabays2,	  A.	  Eskandari1,	  P.	  Michel1	  	  1	  Stroke	  Center,	  Neurology	  Service	  2	  Cardiology	  Service	  from	  the	  Centre	  Hospitalier	  Universitaire	  Vaudois	  and	  University	  of	  Lausanne,	  Lausanne,	  Switzerland	  	  
Abstract	  
	  
Introduction	  	  Paradoxical	  embolism	  from	  right-­‐to-­‐left	  shunt	  through	  a	  patent	  foramen	  ovale	  (PFO)	  is	  a	  well-­‐characterized	  cause	  of	  embolic	  strokes	  of	  undetermined	  source	  (ESUS).	  In	  order	  to	  better	   understand	   the	   pathogenic	   role	   of	   atrial	   septum	   defects	   (ASD),	   we	   compared	  them	  with	  ESUS	  of	  high	  and	  low	  likelihood	  of	  being	  related	  to	  PFO.	  	  
Methods	  	  In	   the	   Acute	   STroke	   Registry	   and	   Analysis	   of	   Lausanne	   (ASTRAL),	   we	   calculated	  prevalence	   of	   PFO	   and	   ASD	   in	   ESUS	   patient	   undergoing	   echocardiography,	   and	   odds	  ratios	  (OR)	  when	  to	  compared	  to	  non-­‐cryptogenic	  strokes.	  Using	  the	  Risk	  of	  Paradoxical	  Embolism	  (RoPE)	  score,	  we	  divided	  cryptogenic	  PFO	  patients	  in	  high	  (HL-­‐PFO,	  RoPE	  8-­‐10)	   and	   low-­‐likelihood	   (LL-­‐PFO,	   RoPE	   0-­‐4)	   PFO-­‐related	   stroke.	   We	   then	   performed	  univariate	   comparison	   of	   epidemiological,	   clinical	   and	   radiological	   variables	   of	   both	  group	  with	  ESUS	  ASD	  patients.	  	  	  
Results	  	  Among	  all	  ESUS,	  prevalence	  for	  ASD	  and	  PFO	  were	  1.3%	  and	  36.8%	  respectively.	  When	  compared	   to	  non-­‐cryptogenic	   stroke,	  ASD	   and	  PFO	  were	   associated	  with	  ESUS	   (OR	  of	  5.2,	  CI=	  1.6-­‐16.6,	   and	  2.8,	  CI=	  2.1-­‐3.8).	  Compared	  with	  HL-­‐PFO,	  ASD	  were	  older,	  more	  often	  female,	  had	  more	  cardiovascular	  risk	  factors	  (CVRF)	  and	  silent	  strokes.	  Compared	  with	   LL-­‐PFO,	   ASD	   group	   was	   significantly	   younger,	   more	   often	   female,	   and	   had	   less	  CVRF.	   No	   differences	   were	   found	   for	   clinical	   and	   radiological	   characteristics	   and	  outcome.	  	  	  
Conclusion	  	  In	   ESUS,	   ASD	   seems	   to	   be	   a	   rare	   but	   significant	   stroke	   risk	   factor.	   Given	   that	  characteristics	  of	  such	  patients	  lie	  in-­‐between	  high	  and	  low-­‐likelihood	  paradoxical	  PFO-­‐stroke,	   a	   thorough	  workup	   for	  other	   stroke	  mechanisms	   is	  warranted	   in	  ASD	  patients	  before	  routine	  ASD	  closure.	  	  
	  
	  
Key	  words	  Atrial	  septal	  defect	  -­‐	  Patent	  foramen	  ovale	  -­‐	  Paradoxical	  embolism	  -­‐	  Embolic	  stroke	  of	  undetermined	  source	  	  	  	   	  
	   	   	  
	   3	  
Introduction	  	  Stroke	  is	  a	  major	  cause	  of	  mortality	  and	  disability	  worldwide.	  Patients	  with	  stroke	  are	  at	  high	   risk	   of	   further	   cerebrovascular	   events,	   making	   the	   identification	   of	   the	   etiology	  essential	   for	   secondary	   prevention.	   A	   large	   majority	   of	   ischemic	   stroke	   is	   caused	   by	  well-­‐defined	  mechanism,	  each	  associated	  with	  a	  particular	  presentation,	  recurrence	  risk,	  and	  a	  specific	  secondary	  prevention	  (1,2).	  Despite	  technological	  progress,	  around	  25%	  of	   all	   ischemic	   strokes	   remain	   of	   unknown,	   or	   “cryptogenic”	   origin	   (3–5).	   Given	   that	  most	   such	   strokes	   are	   due	   to	   thromboembolic	   events,	   the	   term	   Embolic	   Strokes	   of	  Undetermined	  Source	  (ESUS)	  has	  been	  created	  and	  defined	  as	  non-­‐lacunar	  brain	  infarct	  without	   proximal	   arterial	   stenosis,	   major-­‐risk	   cardio	   embolic	   source,	   or	   any	   specific	  cause	   of	   stroke	   (6).	   Paradoxical	   embolism	   through	   a	   right-­‐to-­‐left	   shunt	   is	   a	   well-­‐recognized	  candidate	  for	  ESUS	  (7).	  The	  most	  common	  paradoxical	  embolization	  occurs	  through	  a	  patent	  foramen	  ovale	  (PFO),	  which	  acts	  as	  a	  flap-­‐like	  valve,	  allowing	  transient	  right-­‐to-­‐left	  shunt	  during	  Valsalva	  or	  early	  systole.	  Many	  case	  of	  direct	  visualization	  of	  thrombus	  in	  transit	  through	  the	  PFO	  have	  been	  reported.	  Atrial	  septal	  defect	  (ASD)	  with	  a	  persistent,	  but	  invertible	  left-­‐to-­‐right	  shunt	  is	  a	  much	  rarer	  cause,	  but	  has	  a	  potentially	  higher	  recurrence	  rate	  (7,8).	  The	  pathogenicity	   of	   a	   PFO	   in	   patients	  with	   cryptogenic	   stroke	   and	   recurrence	  risk	   have	   recently	   been	   better	   defined	  with	   the	  Risk	   of	   Paradoxical	   Embolism	   (RoPE)	  score	  (9–11).	  Also,	  PFO	  related	  strokes	  have	  some	  particular	  radiological	  presentation,	  ie.	   they	   tend	   to	   be	   large,	   radiologically	   apparent,	   superficially	   located	   or	   unassociated	  with	  prior	  radiological	  infarcts	  (12).	  On	  the	  other	  hand,	  the	  available	  literature	  on	  ASD	  is	  much	   less	  clear	   regarding	   its	  pathogenic	   role	  and	  recurrence	  risk	   in	   stroke.	  Currently,	  most	  ASD	  in	  patients	  with	  cryptogenic	  stroke	  are	  closed,	  also	  because	  of	  the	  increased	  risk	  of	  such	  patients	  for	  cardiac	  insufficiency,	  pulmonary	  hypertension	  and	  arrhythmia	  (13,14).	  	   Assuming	  that	  patients	  with	  a	  high	  likelihood	  of	  PFO-­‐related	  stroke	  constitute	  a	  model	   of	   a	   paradoxical	   stroke	  with	   epidemiological,	   clinical	   and	   radiological	   patterns,	  we	   compared	   such	   patients	   with	   cryptogenic	   ASD	   stroke	   patients	   in	   order	   to	   better	  understand	  the	  potential	  pathogenicity	  of	  ASD.	  Knowledge	   from	  such	  analyses	  may	  be	  useful	  to	  determine	  whether	  stroke	  in	  patients	  with	  ASD	  need	  further	  work-­‐up	  for	  other	  causes	  of	  ESUS,	  and	  aggressive	  treatment	  such	  as	  ASD	  closure.	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Methods	  We	  used	  the	  data	   from	  the	  Acute	  STroke	  Registry	  and	  Analysis	  of	  Lausanne	  (ASTRAL)	  which	  is	  a	  registry	  cohort	  of	  all	  acute	  ischemic	  stroke	  (AIS)	  patients	  admitted	  since	  2003	  to	  the	  stroke	  unit	  and/or	  intensive	  care	  unit	  of	  the	  CHUV	  within	  24	  hours	  after	  last-­‐well	  time,	  as	  published	  previously	  (3).	  To	  enrich	  the	  ASD	  population,	  we	  also	  added	  patients	  with	   ischemic	   stroke	   and	   imaging	   positive	   transient	   ischemic	   attack	   (TIA)	   from	   the	  parallel	   registry	   called	   «	   ASTRAL-­‐E	   »	   containing	   all	   patients	   excluded	   from	   ASTRAL	  because	  of	  arrival	  >24	  hours	  after	  stroke	  onset	  or	  TIA.	  Furthermore,	  we	  added	  patients	  diagnosed	  with	  ASD	  and	   stroke	  during	   the	   same	  observation	  period	  by	  one	  of	   the	   co-­‐authors	  (AD,	  cardiologist)	  at	  the	  neighbouring	  Morges	  county	  hospital.	  	  For	   the	   ASD	   group,	   we	   selected	   all	   ASTRAL,	   ASTRAL-­‐E	   and	   Morges	   hospital	  patients	  with	  ASD	  on	  transthoracic	  (TTE),	  transoesophageal	  echocardiography	  (TEE),	  or	  both.	   All	   echocardiographic	   images	   were	   reanalyzed	   by	   one	   of	   the	   authors	   (AD)	   to	  confirm	   the	   presence	   of	   the	   ASD.	   ASD	   was	   defined	   as	   a	   tissue	   defect	   in	   the	   septum	  primum	  with	  either	  spontaneous	  left	  to	  right	  shunting,	  and/or	  with	  right	  to	  left	  shunting	  with	  microbubbles	  injection.	  Microbubble	  injection	  was	  not	  required	  for	  ASD	  diagnosis.	  Occasionally,	   the	   ASD	   was	   only	   diagnosed	   at	   the	   time	   of	   closure	   of	   a	   presumed	   PFO	  based	   on	   intracardiac	   or	   transoephageal	   imaging.	   PFO	   was	   defined	   as	   right	   to	   left	  passage	  of	  microbubbles	  after	  their	  intravenous	  injection,	  either	  spontaneously	  or	  with	  a	  Valsalva	  maneuver,	  through	  a	  lack	  of	  apposition	  of	  the	  septum	  primum.	  Simultaneous	  presence	  of	  ASD	  and	  PFO	  was	  also	   searched.	  ASA	  was	  defined	  as	  a	  more	   than	  11	  mm	  excursion	  of	  the	  interatrial	  septum	  on	  TTE	  and/or	  TEE.	  	  In	   all	   patients	   (ASTRAL	  and	  other),	   a	   large	   range	  of	   parameters	  were	   collected	  and	   then	   analyzed	   retrospectively:	   demographics,	   cardiovascular	   risk	   factors,	   clinical	  symptoms	   and	   examination,	   and	   other	   features	   of	   the	   stroke	   (affected	   side,	   vascular	  territory,	   brain	   structures	   affected,	   cortical	   vs.	   subcortical	   involvement,	   The	   National	  Institutes	   of	  Health	   Stroke	   Scale	   (NIHSS)	   score	   at	   admission).	   Acute	   brain	   imaging	   on	  admission	   consisted	   mostly	   of	   multimodal	   CT	   imaging	   including	   CT-­‐perfusion	   (64	  detectors	   since	   2005),	   and	   in	   selected	   patients	   acute	   or	   subacute	  MRI	   and	   repeat	   CT	  scan.	  Experiences	  neuroradiologists	  reviewed	  all	  neuroimages	  for	  the	  topography	  of	  the	  stroke	  lesions	  (cortical,	  subcortical,	  brainstem)	  and	  for	  silent	  stroke	  lesions.	  At	  least	  one	  arterial	   study	  of	   cervical	   and	   cerebral	   arteries	   (usually	  CT-­‐angiography	  on	  admission)	  was	  obtained	  in	  all	  patients	  and	  a	  minimum	  of	  24	  hour	  continuous	  cardiac	  monitoring	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for	  search	  of	  stroke	  causes.	  Additional	  exams	  for	  rare	  causes	  of	  stroke	  were	  performed	  if	  clinically	   indicated.	   Stroke	   and	  TIA	   recurrences	   and	   the	  modified	  Rankin	   score	   (mRS)	  were	   assessed	   by	   mRS-­‐certified	   personnel	   in	   an	   unblinded	   manner	   at	   the	   outpatient	  clinic	   or	   with	   a	   structured	   telephone	   interview	   at	   3	   and	   12	   months.	   Outcome	   was	  considered	  favorable	  if	  the	  mRS	  was	  ≤2	  in	  patients	  with	  a	  prestroke	  mRS	  ≤2.	  	   In	  order	  to	  calculate	  the	  overall	  prevalence	  of	  ASD	  and	  PFO	  in	  an	  ischemic	  stroke	  population,	  we	  used	  all	  patients	  undergoing	  echocardiography	  in	  ASTRAL	  and	  calculated	  odds	  ratios	  (OR).	  We	  then	  calculated	  OR	  for	  ASD	  and	  PFO	  prevalence	  in	  patients	  with	  a	  defined	  stroke	  cause	  vs.	  ESUS.	  	  	   In	  order	  to	  see	  whether	  ASD	  patients	  resembled	  patients	  with	  PFO	  related	  stoke,	  we	  compared	  their	  demographic	  and	  radiological	  characteristics	  with	  patients	  having	  a	  high	   or	   low	   likelihood	   of	   paradoxical	   embolism:	   we	   used	   the	   RoPE	   score	   in	   order	   to	  divide	   cryptogenic	   PFO	   patients	   in	   ASTRAL	   in	   high	   (HL-­‐PFO,	   RoPE	   8-­‐10,	   PFO	  attributable	   fraction	   of	   84%	   to	   88%)	   and	   low-­‐likelihood	   (LL-­‐PFO,	   RoPE	   0-­‐4,	   PFO	  attributable	   fraction	   of	   0%	   to	   38%)	   of	   PFO	   related	   stroke	   (10).	  We	   removed	   patients	  with	   an	   intermediate	   RoPE	   score	   of	   5-­‐7	   (attributable	   fraction	   of	   34%	   to	   72%)	   (10).	  Patients	   with	   both	   an	   ASD	   and	   a	   PFO	   were	   kept	   in	   the	   ASD	   group	   for	   the	   overall	  analyses,	   but	   the	   comparison	   with	   the	   HL-­‐PFO	   was	   also	   repeated	   with	   the	   ASD-­‐only	  patients.	  	  Nominal	   variables	   were	   expressed	   as	   absolute	   number	   and	   percent,	   and	  continuous	  variables	  as	  median	  and	  interquartile	  range	  (IQR).	  Given	  the	  limited	  number	  of	  ASD	  patients	  available,	  we	  did	  univariate	  comparison	  of	  epidemiological,	  clinical	  and	  radiological	   variables	  of	   the	  ESUS	  ASD	  patients	  with	   the	  HL-­‐PFO	  and	  with	   the	  LL-­‐PFO	  group.	  Statistical	  analysis	  was	  performed	  using	  STATA	  14.0	  statistical	  software.	  Results	  were	   expressed	   as	   odds	   ratios	   and	   95%	   confidence	   Intervals.	   P-­‐value	   <0.05	   was	  considered	  as	  significant.	  The	  local	  ethics	  committee	  approved	  the	  protocol	  of	  this	  study.	  
Results	  	  Between	  January	  2003	  and	  October	  2014,	  2367/3517	  (67.4%)	  of	  all	  AIS	  in	  ASTRAL	  had	  a	  TTE,	  TEE	  or	  both	  and	  were	  included	  in	  our	  analysis.	  993	  of	  all	  strokes	  (28.2%)	  were	  of	  undetermined	   origin	   according	   to	   TOAST	   criteria,	   including	   755	   (76.0%)	   who	  underwent	  echocardiography.	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We	  identified	  12	  AIS	   in	  11	  patients	  with	  an	  ESUS	  and	  an	  ASD.	  10	  of	   these	  were	  ASDs	  only,	  and	  two	  had	  a	  simultaneous	  PFO	  on	  microbubble	  testing.	  Six	  other	  patients	  with	  an	  ASD	  were	  excluded	  from	  the	  cryptogenic	  ASD	  group	  because	  of	  another	  definite	  cause	  of	  stroke	  (n=4)	  or	  because	  of	  imaging	  negative	  TIA	  (n=2)	  (Figure	  1).	  None	  of	  the	  ASD	  patients	  had	  a	  permanent	  right-­‐to-­‐left	  shunt.	  	  	   Misdiagnosis	   of	   atrial	   septum	   pathology	   initially	   occurred	   in	   5	   patients:	   one	  patient	   first	   diagnosed	   as	   PFO	  was	   reclassified	   as	  ASD	  because	   of	   a	   permanent	   septal	  tissue	   defect;	   conversely	   4	   “ASD”	   patients	   were	   reclassified	   as	   PFO	   because	   of	   the	  opposite	   situation.	   	   9	  of	   the	  12	  events	   in	  ESUS	  ASD	  patients	  were	   reported	   in	  women	  (75%)	  and	  their	  median	  age	  was	  50	  years.	  When	  excluding	   the	  2	  events	  with	  an	  ASD-­‐associated	   PFO	   from	   the	   cryptogenic	   ASD	   group,	   8	   of	   the	   10	   patients	   were	   women	  (80%),	  and	  the	  median	  age	  was	  50	  years.	   	  Baseline	  characteristics	  of	  ASD	  patients	  are	  summarized	  in	  Table	  2.	  In	  the	  2367	  ASTRAL	  patients	  undergoing	  echocardiography,	  PFO	  were	  searched	  with	   microbubbles	   injection	   in	   827	   patients.	   Among	   these	   patients,	   the	   overall	   PFO	  prevalence	  was	  36.8%	  (304/827).	  Among	  cryptogenic	  stroke,	   it	  was	  48.5%	  (194/400)	  and	   among	   non-­‐cryptogenic	   strokes	   25.3%	   (101/400).	   Comparing	   cryptogenic	   with	  non-­‐cryptogenic	  patients,	  the	  OR	  was	  2.8	  (2.07	  –	  3.76,	  p<0.01)	  to	  find	  a	  PFO.	  	  Using	   the	   data	   from	   ASTRAL	   (14	   AIS,	   of	   which	   10	   were	   cryptogenic),	   the	  prevalence	  of	  ASD	  in	  all	  strokes	  (cryptogenic	  or	  not)	  examined	  with	  echocardiography	  was	  0.59%	  (14/2367).	   In	  patients	  with	  cryptogenic	  strokes,	   this	   frequency	  was	  1.33%	  (10/754)	   and	   it	  was	  0.26%	   (4/1551)	   in	  non-­‐cryptogenic	   stroke	   (Table	  1).	   Comparing	  cryptogenic	  with	  non-­‐cryptogenic	  patients,	   the	  OR	   for	   the	  presence	  of	  an	  ASD	  was	  5.2	  (Figure	   2).	   The	   ASD-­‐only	   group	   exhibited	   an	   OR	   of	   4.15	   for	   the	   presence	   of	   ASD	   in	  cryptogenic	   vs.	   non-­‐cryptogenic	   stroke	   (8/754	   vs.	   4/1551).	   When	   we	   compared	   the	  proportion	  of	  cryptogenic	  vs.	  non-­‐cryptogenic	  stroke	  within	  ASD	  patients	  (10	  vs.	  4)	  vs.	  PFO	  patients	  (194	  vs.101),	  we	  found	  an	  OR	  of	  1.30	  (Figure	  2,	  non-­‐significant).	  	  	  Among	  the	  cryptogenic	  patients	  with	  PFO,	   the	  HL-­‐PFO	  contained	  55	  events	  and	  the	   LL-­‐PFO	   group	   42.	   In	   the	   HL-­‐PFO	   population,	   median	   age	   was	   29.6	   with	   38.2%	  women.	   The	   LL-­‐PFO	   had	   a	  median	   age	   of	   72.3	   years	   and	   consisted	   of	   57.1%	  woman.	  Baseline	  characteristics	  of	  HL-­‐PFO	  and	  LL-­‐PFO	  are	  summarized	  in	  Table	  2.	  When	   comparing	   ASD	   with	   the	   HL-­‐PFO,	   the	   former	   were	   older,	   more	   often	  female,	   and	  had	  more	   cardiovascular	   risk	   factors	   (CVRF)	   (Tables	  2	   and	  3).	  Half	   of	   the	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ASD	   patients	   had	   2	   CVRF	   or	   more,	   with	   a	   particularly	   high	   prevalence	   of	   arterial	  hypertension	   and	   hyperlipidemia.	   In	   keeping	   with	   the	   higher	   CVRF	   profile,	   three	  patients	  in	  the	  ASD	  group	  had	  a	  previous	  unexplained	  clinical	  stroke	  or	  TIA,	  but	  only	  one	  in	   the	  HL-­‐PFO	  group	  (p=0.02).	  The	  prevalence	  of	  concomitant	  ASA	  was	  comparable	   in	  both	  groups.	  When	  applying	  the	  ROPE	  score	  to	  the	  cryptogenic	  ASD	  patients	  (7;	  IQR	  5-­‐8),	   their	   median	   score	   was	   lower	   than	   in	   the	   HL-­‐PFO	   (8;	   IQR	   8-­‐9,	   p<0.01).	   Median	  admission	   NIHSS	   and	   territory	   affected	   by	   the	   stroke	   were	   similar	   in	   both	   groups.	  Younger	   age	   in	   the	   HL-­‐PFO	   group	   may	   explain	   its	   somewhat	   higher	   proportion	   of	  favorable	  outcome	  at	  3	  and	  12	  months.	  Stroke	  or	  TIA	  recurrence	  at	  12	  months	  was	  low	  in	  ASD	  and	  HL-­‐PFO	  (1/12;	  8%	  and	  1/55;	  2%	  respectively)	  and	  statistically	  not	  different.	  Radiological	  stroke	  localization	  from	  the	  ASD	  group	  tended	  to	  be	  more	  in	  the	  brainstem	  and	  less	  cortical,	  but	  these	  differences	  didn’t	  reach	  statistical	  significance.	  Silent	  strokes	  were	  borderline	  more	  frequently	  found	  in	  ASD	  group	  (2/12;	  17%	  vs.	  1/55;	  2%,	  p=0.07).	  	  When	  comparing	  the	  ASD-­‐only	  patients	  with	  HL-­‐PFO,	  we	  found	  the	  same	  results	  concerning	   demographics,	   PFO	   features,	   prevalence	   of	   major	   risk	   factors,	   preceding	  cerebrovascular	   events,	   stroke	   characteristic,	   outcome,	   and	   territory	   topography.	   The	  two	  patients	  with	  simultaneous	  ASD	  and	  PFO	  very	  similar	  to	  the	  other	  10	  ASD	  events:	  there	  was	  one	  female	  and	  one	  male	  of	  46	  and	  43	  years	  respectively,	  a	  ROPE-­‐score	  of	  8	  and	  no	  silent	  strokes	  on	  imaging.	  	  The	   higher	   prevalence	   of	   silent	   strokes	   in	   ASD	   patients	   (20%	   vs.	   2%,	   p=0.05)	  remained	  borderline.	  One	  ASD	  patient	  had	  two	  chronic	  lesions	  of	  embolic	  appearance	  in	  the	  each	  PICA	  territory	  and	  the	  second	  a	  lacunar	  lesion	  above	  the	  left	  lenticular	  nucleus.	  The	   only	   HL-­‐PFO	   patient	   with	   a	   silent	   stroke	   lesion	   had	   an	   embolic	   appearing	   left	  occipital	  lobe	  scar.	  	  	  When	   comparing	   the	   ASD	   group	   with	   the	   LL-­‐PFO	   group,	   the	   former	   were	  significantly	   younger	   and	   had	   less	   cardiovascular	   risk	   factors	   (Tables	   2	   and	   3).	   The	  ROPE	  score	  was	  significantly	  higher	  in	  the	  ASD	  than	  the	  LL-­‐PFO	  (7;	  IQR	  5-­‐8	  vs.	  3.5;	  IQR	  3-­‐4,	   p<0.01).	   No	   differences	   were	   found	   concerning	   presence	   of	   ASA.	   There	   were	   no	  significant	  differences	  concerning	  previous	  clinical	  stroke	  or	  TIA,	  outcome	  at	  3	  and	  12	  months,	   mortality,	   arterial	   territory	   and	   topography,	   except	   for	   a	   tendency	   of	   more	  strokes	  in	  the	  brainstem	  and	  less	  in	  the	  cortex	  in	  the	  ASD	  group.	  We	  found	  no	  statistical	  differences	  concerning	  presence	  of	  silent	  strokes.	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Discussion	  In	  this	  retrospective	  study	  of	  a	   large	  AIS	  databank,	  we	  found	  a	   low	  prevalence	  of	  ASD;	  both	  ASD	  and	  PFO	  seemed	  to	  be	  associated	  with	  ESUS.	  When	  compared	  cryptogenic	  AIS	  with	  a	  high	  likelihood	  of	  a	  PFO-­‐related	  stroke,	  cryptogenic	  stroke	  patients	  with	  ASD	  had	  a	   higher	   age	   and	   cardiovascular	   profile,	   including	   silent	   strokes	   on	   imaging.	   Stroke	  severity,	   clinical	   and	   radiological	   stroke	   location	   and	   clinical	   outcome	   were	   similar.	  	  When	  compared	  to	  cryptogenic	  AIS	  with	  a	   low	  likelihood	  of	  a	  PFO-­‐related	  stroke,	  ASD	  patients	   were	   younger	   and	   had	   a	   more	   benign	   cardiovascular	   profile.	   Clinical,	  radiological,	  and	  prognostic	  factors	  were	  similar.	  	  Prevalence	   of	   ASD	   in	   ESUS	   is	   low	   compared	   to	   PFO,	   in	   keeping	   with	   its	   low	  prevalence	   in	   the	   general	   population.	   Similar	   to	   PFO,	   its	   pathogenic	   role	   seems	  confirmed	   by	   our	   finding	   of	   a	   higher	   prevalence	   in	   ESUS	   than	   in	   stroke	   with	   a	  determined	  cause	  (OR	  of	  5.2	  for	  ASD,	  and	  2.8	  for	  PFO).	  Our	  OR	  for	  PFO	  is	  identical	  to	  the	  one	   in	   the	  meta-­‐analysis	  of	  Alsheikh-­‐Ali	  et	  al	   (15).	  The	  OR	  for	  ASD	   is	  non-­‐significantly	  higher	  than	  for	  PFO	  in	  this	  small	  sample;	  to	  our	  knowledge,	  OR	  for	  ASD	  association	  with	  strokes	  has	  not	  been	  published	  previously.	  When	   reviewing	   our	   ASD	   and	   PFO	   patients	   for	   this	   study,	   we	   found	   several	  misdiagnoses,	   in	   particular	   an	   overdiagnosis	   of	   ASD	   in	   PFO	   patients.	   	   This	   may	   be	  important	  if	  a	  center	  has	  a	  tendency	  to	  offer	  ASD	  closure	  to	  the	  majority	  of	  such	  patients.	  The	   exact	  mechanism	   for	   the	   pathogenicity	   of	   ASD	   is	   not	   yet	   fully	   understood.	  Due	  to	  the	  permanent	  opening	  of	  the	  ASD,	  a	  left-­‐to-­‐right	  shunt	  is	  usually	  present	  in	  such	  patients.	   For	   paradoxical	   embolization,	   shunt	   inversion	   is	   required,	   which	   can	   occur	  transiently	   during	   Valsalva,	   and	   permanent	   in	   severe	   ASDs	   with	   pulmonary	  hypertension	   (“Eisenmenger	   syndrom”).	   Unlike	   in	   PFO,	   it	   is	   not	   clear	   whether	   other	  structural	   septum	   findings	   in	   ASD	   are	   associated	  with	   a	   particularly	   high	   stroke	   risk.	  However,	  a	  small	  size	  ASD	  has	  recently	  been	  associated	  with	  a	  greater	  risk	  of	  embolic	  events,	  similar	  to	  PFO	  (11,13).	  In	  our	  population,	  we	  found	  no	  difference	  concerning	  the	  presence	  of	  an	  ASA	  among	  the	  three	  populations.	  	  	  When	   compared	   to	   HL-­‐PFO,	   ASD	   patient	   are	   significantly	   older,	   and	   they	   are	  younger	   than	   LL-­‐PFO.	   Also	   for	   other	   risk	   factors	   including	   preceding	   cerebrovascular	  events	   and	   silent	   infarctions,	   ASD	   patient	   with	   ESUS	   seems	   to	   be	   an	   intermediate	  population	  between	  patients	  with	  high	  and	  low	  probability	  of	  paradoxical	  embolism.	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   We	   report	   a	   female	  predominance	  of	  ASD	   in	  ESUS	  when	   compared	   to	  both	  LL-­‐PFO	  and	  HL-­‐PFO.	  This	  finding	  is	  likely	  explained	  by	  a	  higher	  prevalence	  of	  ASD	  in	  girls	  at	  birth,	  whereas	  PFO	  prevalence	  is	  similar	  in	  both	  sexes	  (16,17).	  These	  results	  are	  similar	  to	  a	  previous	  report	  comparing	  ASD	  and	  PFO	  patients	  referred	  for	  percutaneous	  closing	  (13).	  	   Radiologically,	   PFO	   related	   stroke	   are	   typically	   large,	   apparent,	   superficially	  located	   or	   unassociated	   with	   prior	   radiological	   infarcts	   (12).	   Our	   results	   show	   no	  statistical	  differences	  in	  radiological	  presentation	  and	  stroke	  localization.	  Silent	  cerebral	  infarction	  were	   somewhat	  more	   present	   in	   ASD	   and	   LL-­‐PFO	   than	   in	   the	  HL-­‐PFO;	   this	  may	  be	  explained	  by	  the	  higher	  risk	  factor	  profile	  (as	  exemplified	  by	  an	  ASD	  with	  a	  silent	  lacunar	  lesion),	  or	  by	  a	  unproven	  higher	  tendency	  of	  ASD	  for	  recurrent	  embolic	  stroke.	  	  	  	   Unadjusted	   functional	   outcome	  at	  3	   and	  12	  months	   seemed	   similar	   in	   all	   three	  groups	   and	   recurrence	   rates	   were	   too	   low	   for	   meaningful	   statistical	   comparisons,	  although	  HL-­‐PFO	  seems	  to	  have	  the	  lowest	  risk,	  as	  is	  well	  known	  from	  previous	  studies	  (11,18).	  	   The	  RoPE	  score	  has	  been	  designed	  for	  patients	  with	  PFO,	  in	  order	  to	  assess	  PFO	  pathogenicity,	   and	   consequently	   probability	   of	   paradoxical	   embolism.	   Assuming	   that	  paradoxical	   embolism	   from	   right-­‐to-­‐left	   shunt	   is	   the	   common	  mechanism	   in	   PFO	   and	  ASD	   related	   stroke,	   we	   also	   applied	   the	   RoPE	   score	   to	   our	   ASD	   patients.	   The	  intermediate	   value	   between	   HL-­‐	   and	   LL-­‐PFO	   groups	   are	   consistent	   with	   the	  intermediate	   age	   and	   risk	   factor	   profile	   in	   ASD	   patients,	   and	   support	   the	   notion	   that	  some	   but	   not	   all	   AIS	   in	   these	   patients	   are	   ASD	   related.	   Similar	   to	   LL-­‐PFO	   patients,	   a	  significant	  proportion	  of	  ESUS	  in	  ASD	  patients	  may	  be	  related	  to	  other	  mechanisms	  such	  as	   covert	   paroxysmal	   atrial	   fibrillation	   or	   atherosclerotic	   sources	   (6,7).	   Therefore,	   a	  careful	   work-­‐up	   by	   an	   experienced	   cerebrovascular	   center	   seems	   warranted	   before	  otherwise	  asymptomatic	  ASD	  closure	  is	  considered.	  The	  most	  important	  limitation	  for	  this	  study	  is	  the	  low	  number	  of	  ASD	  patients,	  not	   allowing	   for	   a	   multivariate	   analysis.	   Secondly,	   the	   study	   design	   is	   retrospective,	  observational,	  and	  non-­‐randomized.	  Moreover,	  this	  is	  a	  single	  center	  study,	  which	  may	  not	  have	  a	  population	  representative	  of	  other	  setting	  for	  acute	  stroke	  care.	  	  In	   conclusion,	   in	   a	   limited	   number	   of	   ASD	   patients	  with	   ESUS,	  we	   confirmed	   a	  likely	   association	   of	   ASD	   and	   AIS,	   and	   found	   an	   intermediate	   likelihood	   of	   ASD	   being	  causally	   related	   to	   the	   stroke.	   This	   supports	   detailed	   etiological	   work-­‐up	   of	   such	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patients	  with	   selective	   closure	  of	  ASD.	  Further	   systematic	   study	  of	  ASD	  and	  ESUS	  and	  the	  applicability	  of	  the	  RoPE	  score	  in	  ASD	  are	  required	  in	  larger	  samples	  of	  patients.	  
Tables	  and	  Figures	  
	  
Figure	  1.	  Inclusion	  and	  exclusion	  flow	  diagram	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Image	  1.	  Transoesophageal	  echocardiography	  of	  ASD	  and	  PFO	  	  




Table	  1.	  ASD	  and	  PFO	  prevalence	  among	  ASTRAL	  patients	  	  
	  
ASD	   PFO	  	  Number	  of	  events	   14	   304	  Reference	  population	  a	   2367	   827	  Overall	  prevalence	  	   0.59%	   36.8%	  Cryptogenic	  events	   10	   194	  Prevalence	  among	  cryptogenic	  stroke	   1.33%	   48.5%	  Definite	  cause	   4	   101	  Prevalence	  among	  stroke	  of	  definite	  cause	  	   0.26%	   25.3%	  	  a	   For	   overall	   prevalence,	   ASD	   patients	   were	   compared	   to	   all	   ASTRAL	   patients	   who	   had	   transthoracic	  and/or	  transoesophageal	  echocardiography,	  whereas	  PFO	  patients	  were	  compared	  to	  all	  ASTRAL	  patients	  who	  had	  echocardiography	  with	  injection	  of	  air	  microbubble.	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Figure	  2.	  ASD	  and	  PFO	  association	  with	  ESUS	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Table	  2.	  Baseline	  characteristics	  of	  ESUS	  patients	  with	  ASD	  and/or	  PFO	  	  
	  Continuous	   variables	   are	   presented	   as	  median±interquartile	   range.	  Nominal	   variables	   are	   presented	   as	  absolute	   number	   and	   percent	   (percent	   refers	   to	   recorded	   values	   only;	   missing	   values	   have	   been	  excluded).	   ASA,	   atrial	   septal	   aneurysm;	   CAD,	   coronary	   artery	   disease;	   BMI,	   body	   mass	   index;	   NIHSS,	  national	  institute	  of	  health	  stroke	  score.	  a	  Refers	  to	  previous	  clinical	  stroke	  or	  transient	  ischemic	  attack	  (TIA).	   	  









Demographics	   	   	   	   	  	  	  	  Female	  sex	   9	  (75%)	   8	  (80%)	   21	  (38%)	   24	  (57%)	  	  	  	  Age,	  y	   49.5	  (41.7-­‐55.96)	   49.98	  (39.8-­‐60.7)	   29.64	  (25.09-­‐36.72)	   72.29	  (66.67-­‐78.01)	  
PFO	  features	   	   	   	   	  	  	  	  RoPE	   7	  (5-­‐8)	   6.5	  (5	  to	  7.75)	   8	  (8-­‐9)	   3.5	  (3-­‐4)	  	  	  	  ASA	   8	  (67%)	   7	  (70%)	   26	  (47%)	   17	  (41%)	  
Major	  Risk	  Factor	   	   	   	   	  	  	  	  Hypertension	   4	  (33%)	   4	  (40%)	   0	   35	  (83%)	  	  	  	  Diabetes	   0	   0	   1	  (2%)	   5	  (12%)	  	  	  	  Smoking	   2	  (17%)	   2	  (20%)	   16	  (29%)	   10	  (24%)	  	  	  	  Hyperlipidemia	   7	  (58%)	   6	  (60%)	   14	  (26%)	   33	  (79%)	  	  	  	  Atrial	  Fibrillation	   0	   0	   0	   0	  
	  	  	  CAD	   1	  (8%)	   1	  (10%)	   0	   0	  	  	  	  BMI	   6	  (50%)	   4	  (40%)	   13	  (27%)	   18	  (45%)	  	  	  	  Migraine	   3	  (25%)	   2	  (20%)	   12	  (22%)	   2	  (5%)	  	  	  	  Previous	  strokea	   3	  (25%)	   3	  (30%)	   1	  (2%)	   19	  (45%)	  	  	  	  ≥2	  Risk	  Factors	   6	  (50%)	   5	  (50%)	   9	  (20%)	   36	  (92%)	  
Stroke	  characteristics	   	   	   	   	  	  	  	  Admission	  NIHSS	  	   4	  (3-­‐13.25)	   7.5	  (3.5-­‐13.75)	   4	  (1-­‐9.5)	   7	  (4-­‐10.75)	  	  	  	  Anterior	  circulation	   8	  (67%)	   7	  (70%)	   35	  (64%)	   31(74%)	  	  	  	  Posterior	  circulation	   4	  (33%)	   3	  (30%)	   20	  (36%)	   11	  (26%)	  
Outcome	   	   	   	   	  	  	  	  Favorable	  at	  3	  months	   7	  (58%)	   5	  (50%)	   35	  (76%)	   19	  (49%)	  	  	  	  Favorable	  at	  12	  months	   7	  (58%)	   5	  (50%)	   36	  (80%)	   19	  (49%)	  	  	  	  Mortality	  at	  12	  months	   0	   0	   0	   2	  (5%)	  	  	  	  	  	  	  Recurrence	  over	  12	  	  	  	  	  	  	  	  	  	  	  	  months	  (stroke	  or	  TIA)	   1	  (8%)	   1	  (10%)	   1	  (2%)	   3	  (8%)	  
Radiology	   	   	   	   	  
Territory	  Topography:	   	   	   	   	  	  	  	  Cortical	   2	  (17%)	   1	  (10%)	   19	  (35%)	   15	  (36%)	  	  	  	  Subcortical	   1	  (8%)	   1	  (10%)	   5	  (9%)	   5	  (12%)	  	  	  	  Cortical	  &	  subcortical	   4	  (33%)	   4	  (40%)	   16	  (29%)	   14	  (33%)	  	  	  	  Brainstem	  (together)	   5	  (42%)	   4	  (40%)	   15	  (27%)	   8	  (19%)	  	  	  	  Silent	  strokes	   2	  (17%)	   2	  (20%)	   1	  (2%)	   15	  (38%)	  
	   	   	  
	   14	  
Table	  3.	  Summary	  of	  results	  	  
	   ASD	  vs.	  HL-­‐PFO	   	   ASD-­‐only	  vs.	  HL-­‐PFO	   	   ASD	  vs.	  LL-­‐PFO	  
	   OR	   OR-­‐CI	   p	   	   OR	   OR-­‐CI	   p	   	   OR	   OR-­‐CI	   p	  
Demographics	   	   	   	   	   	   	   	   	   	   	   	  	  	  	  Female	  sex	   4.9	   1.2-­‐20	   <0.01	   	   6.5	   1.3-­‐33.5	   0.03	   	   2.3	   0.5-­‐9.5	   0.27	  	  	  	  Age,	  y	   1.1	   1.1-­‐1.2	   <0.01	   	   1.1	   1.0-­‐1.2	   <0.01	   	   0.8	   0.7-­‐0.9	   <0.01	  
PFO	  features	   	   	   	   	   	   	   	   	   	   	   	  	  	  	  RoPE	   0.2	   0.05-­‐0.6	   <0.01	   	   0.2	   0.04-­‐0.6	   <0.01	   	   5.3	   1.7-­‐16.5	   <0.01	  	  	  	  ASA	   2.2	   0.6-­‐8.3	   0.23	   	   2.6	   0.6-­‐11.1	   0.20	   	   2.9	   0.8-­‐11.3	   0.12	  
Major	  Risk	  Factor:	   	   	   	   	   	   	   	   	   	   	   	  	  	  	  Hypertension	   NA	   NA	   <0.01	   	   NA	   NA	   p<0.01	   	   0.1	   0.02-­‐0.5	   <0.01	  	  	  	  Diabetes	   NA	   NA	   0.82	   	   NA	   NA	   0.74	   	   NA	   NA	   0.39	  	  	  	  Smoking	   0.5	   0.1-­‐2.5	   0.39	   	   0.6	   0.1-­‐3.2	   0.56	   	   0.6	   0.1-­‐3.4	   0.60	  	  	  	  Hyperlipidemia	   3.9	   1.1-­‐14.3	   0.04	   	   4.2	   1.0-­‐17.0	   0.05	   	   0.4	   0.1-­‐1.5	   0.17	  	  	  	  Atrial	  Fibrilation	   NA	   NA	   NA	   	   NA	   NA	   NA	   	   NA	   NA	   NA	  	  	  	  CAD	   NA	   NA	   0.11	   	   NA	   NA	   0.09	   	   NA	   NA	   0.15	  	  	  	  BMI	   2.8	   0.8-­‐10.1	   0.12	   	   1.8	   0.4-­‐7.6	   0.40	   	   0.9	   0.3-­‐3.1	   0.89	  	  	  	  Migraine	   1.2	   0.3-­‐5.0	   0.84	   	   0.9	   0.2-­‐4.7	   0.88	   	   6.7	   0.97-­‐45.9	   0.05	  	  	  	  Previous	  stroke	  a	   18	   1.7-­‐192.7	   0.02	   	   23.1	   2.1-­‐254.2	   0.01	   	   0.4	   0.1-­‐1.7	   0.22	  	  	  	  ≥2	  risk	  factors	   4.1	   1.1-­‐15.8	   0.04	   	   4.1	   1.0	  -­‐17.3	   0.05	   	   0.1	   0.02-­‐0.4	   <0.01	  
Stroke	  characteristics	   	   	   	   	   	   	   	   	   	   	   	  	  	  	  Admission	  NIHSS	  	   1.0	   0.95-­‐1.1	   0.57	   	   1.0	   0.96-­‐1.1	   0.34	   	   1.0	   0.9-­‐1.1	   0.77	  	  	  	  Anterior	  circulation	   1.1	   0.3-­‐4.3	   0.84	   	   1.3	   0.3-­‐5.7	   0.70	   	   0.7	   0.2-­‐2.8	   0.63	  	  	  	  Posterior	  circulation	   0.9	   0.2-­‐3.3	   0.84	   	   0.8	   0.2-­‐3.2	   0.70	   	   1.4	   0.35-­‐5.6	   0.63	  
Outcome	   	   	   	   	   	   	   	   	   	   	   	  	  	  	  Favorable	  at	  3	  months	   0.4	   0.1-­‐1.7	   0.23	   	   0.3	   0.1-­‐1.3	   0.11	   	   1.5	   0.4-­‐5.45	   0.56	  	  	  	  Favorable	  at	  12	  months	   0.4	   0.1-­‐1.4	   0.13	   	   0.3	   0.1-­‐1.1	   0.06	   	   1.5	   0.4-­‐5.45	   0.56	  	  	  	  Mortality	  at	  12	  months	   NA	   NA	   0.52	   	   NA	   NA	   0.47	   	   NA	   NA	   0.75	  	  	  	  Recurrence	  over	  12	  months	  (stroke	  or	  TIA)	   4.0	   0.2-­‐69.1	   0.52	   	   4.9	   0.3-­‐85.6	   0.28	   	   1.1	   0.1-­‐11.6	   0.94	  
Radiology	   	   	   	   	   	   	   	   	   	   	   	  
Territory	  Topography:	   	   	   	   	   	   	   	   	   	   	   	  	  	  	  Cortical	   0.4	   0.1-­‐1.9	   0.24	   	   0.2	   0.02-­‐1.79	   0.15	   	   0.4	   0.1-­‐1.9	   0.22	  	  	  	  Subcortical	   0.9	   0.1-­‐8.6	   0.93	   	   1.1	   0.1-­‐10.7	   0.93	   	   0.7	   0.1-­‐6.4	   0.73	  	  	  	  Cortical	  &	  subcortical	   1.2	   0.3-­‐4.6	   0.77	   	   1.6	   0.4-­‐6.5	   0.49	   	   1	   0.3-­‐3.9	   1.00	  	  	  	  Brainstem	  (together)	   1.9	   0.5-­‐6.9	   0.33	   	   1.8	   0.4-­‐7.2	   0.42	   	   3.0	   0.8-­‐12.1	   0.12	  	  	  	  Silent	  strokes	   10	   0.8-­‐121.2	   0.07	   	   13	   1.01-­‐154.4	   0.05	   	   0.3	   0.1-­‐1.7	   0.19	  	  Univariate	   comparison	   of	   epidemiological,	   clinical	   and	   radiological	   variables	   of	   the	   ESUS	   ASD	   patients	  with	  the	  high	  and	  low	  likelihood	  of	  PFO	  related	  stoke	  group	  (HL-­‐PFO	  and	  LL-­‐PFO	  group).	  NA	  indicates	  not	  available	  	  (OR	  cannot	  be	  calculated	  because	  of	  a	  value	  of	  zero	  in	  certain	  groups).	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Figure	  3.	  Forest	  plot	  summarizing	  significant	  results	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